Stem cells from amniotic fluid tested for progressive MS – but trial pulled
NCT ID NCT06841068
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to test whether stem cells from amniotic fluid, injected into the spinal fluid, could safely help people with progressive multiple sclerosis (MS). The trial was designed for adults aged 18–60 with primary or secondary progressive MS. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amniotic fluid stem cells (CD117-positive)
- What this could lead to
- If this therapy proves safe and effective, it could slow disability progression in people with progressive multiple sclerosis.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data exist. Stem cell therapies for MS are still experimental and carry risks like infection or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, PROGRESSIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health
Charlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Could a simple injection replace an IV for MS treatment?
- Could a common supplement fight fatigue in progressive MS?
- Tears may replace spinal taps for MS diagnosis
- Nurse-Led video calls aim to empower MS patients